Work

Cuog Phase Ii Randomized Study of Custirsen (ogx-011) Combination Therapy in Patients With Castrate Resistant Prostate Cancer (crpc) Who Relapsed on or Within Six Months of 1st-line Docetaxel Therapy

FWCI: 0.279
Cites:
Cited by: 1
Related to: 10